These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33825966)

  • 1. Coming Soon: The First-Ever Drug(s) for Refractory Chronic Cough.
    Dicpinigaitis PV
    Lung; 2021 Apr; 199(2):83-84. PubMed ID: 33825966
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
    Muccino D; Green S
    Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough.
    Dicpinigaitis PV; McGarvey LP; Canning BJ
    Lung; 2020 Aug; 198(4):609-616. PubMed ID: 32661659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
    Garceau D; Chauret N
    Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery and development of gefapixant.
    Ford AP; Dillon MP; Kitt MM; Gever JR
    Auton Neurosci; 2021 Nov; 235():102859. PubMed ID: 34403981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefapixant: First Approval.
    Markham A
    Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
    Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
    Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications.
    Marucci G; Dal Ben D; Buccioni M; Martí Navia A; Spinaci A; Volpini R; Lambertucci C
    Expert Opin Ther Pat; 2019 Dec; 29(12):943-963. PubMed ID: 31726893
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Druggable negative allosteric site of P2X3 receptors.
    Wang J; Wang Y; Cui WW; Huang Y; Yang Y; Liu Y; Zhao WS; Cheng XY; Sun WS; Cao P; Zhu MX; Wang R; Hattori M; Yu Y
    Proc Natl Acad Sci U S A; 2018 May; 115(19):4939-4944. PubMed ID: 29674445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
    Birring SS; Dicpinigaitis PV; Smith JA; Morice AH; McGarvey LP; Pavord ID; Nguyen AM; Schelfhout J; Li Q; Iskold B; Green SA; Philip G; Muccino DR; La Rosa C
    Am J Respir Crit Care Med; 2023 Jun; 207(11):1539-1542. PubMed ID: 36996347
    [No Abstract]   [Full Text] [Related]  

  • 13. Gefapixant for chronic cough.
    Thomas D; Gibson PG
    Lancet; 2022 Mar; 399(10328):886-887. PubMed ID: 35248173
    [No Abstract]   [Full Text] [Related]  

  • 14. [Gefapixant in the treatment of chronic coughing].
    Kühlein T; Hasford C; Nitschmann S
    Inn Med (Heidelb); 2023 Apr; 64(4):409-412. PubMed ID: 36705677
    [No Abstract]   [Full Text] [Related]  

  • 15. Managing unexplained chronic cough in adults: what are the unmet needs?
    Irwin RS; French CL; Madison JM
    Lancet Respir Med; 2020 Aug; 8(8):745-747. PubMed ID: 32109424
    [No Abstract]   [Full Text] [Related]  

  • 16. DT-0111: a novel drug-candidate for the treatment of COPD and chronic cough.
    Pelleg A; Xu F; Zhuang J; Undem B; Burnstock G
    Ther Adv Respir Dis; 2019; 13():1753466619877960. PubMed ID: 31558105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2X3 receptor antagonist in chronic cough.
    Turner RD; Rajakulasingam RK; Bhowmik A; Bothamley GH
    Lancet; 2015 Jul; 386(9990):244. PubMed ID: 26194521
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-induced chronic cough and the possible mechanism of action.
    Ding H; Shi C; Xu X; Yu L
    Ann Palliat Med; 2020 Sep; 9(5):3562-3570. PubMed ID: 32921095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors.
    Obrecht AS; Urban N; Schaefer M; Röse A; Kless A; Meents JE; Lampert A; Abdelrahman A; Müller CE; Schmalzing G; Hausmann R
    Neuropharmacology; 2019 Nov; 158():107749. PubMed ID: 31461640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones.
    Szántó G; Makó A; Vágó I; Hergert T; Bata I; Farkas B; Kolok S; Vastag M
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3905-12. PubMed ID: 27426300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.